W
WAVEMAN · COMPANY
ADPT · Adaptive Biotechnologies Corp
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

ADPT

Adaptive Biotechnologies Corp
PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001478320
FORM 144 · 20☆ WATCH
INSIDER NET · 180D
-$78.9M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
161
13F, latest reported quarter
REVENUE GROWTH
+54.8%
XBRL, annual
NET MARGIN
-21.5%
CONVERSIONS · 180D
68
codes C/M, not in net · $13.3M priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$78.9M over 180 days
-$49.7M over 90 days
below 97% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
161 funds added or opened last quarter
more than 81% of Pharma & Biotech
REVENUE
+54.8% year over year
more than 80% of Pharma & Biotech
MARGIN
-21.5% net margin
below 51% of Pharma & Biotech
BUYBACKS
$25.0M repurchased, FY to 2026-06-30
below 60% of Pharma & Biotech
SHORT
7.8% of shares outstanding short · 4.4 days to cover · settled 2026-07-31
more than 68% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$78.9M across 11 people in 180 days.
161 funds added or opened positions in the latest 13F quarter, of 303 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +89.1%
+89.1%12M
-3%+33%+69%+106%2025-092025-102025-122026-032026-052026-072026-09 2026-08-17 · ROBINS CHAD M sold $8.0M2026-08-18 · ROBINS CHAD M sold $6.8M2026-07-21 · ROBINS HARLAN S sold $6.1M2025-11-21 · BENZENO SHARON sold $5.2M2026-07-02 · ROBINS HARLAN S sold $5.2M2025-11-20 · BENZENO SHARON sold $4.9M2026-07-21 · ROBINS HARLAN S sold $4.7M2026-03-02 · ROBINS CHAD M sold $4.6M2026-03-11 · ROBINS HARLAN S sold $4.3M2026-03-11 · ROBINS CHAD M sold $4.3M2026-07-02 · ROBINS HARLAN S sold $3.3M2026-06-29 · BENZENO SHARON sold $3.3M2025-11-28 · PISKEL KYLE sold $3.2M2026-02-27 · ROBINS CHAD M sold $2.9M2026-07-15 · LO FRANCIS sold $2.4M2025-12-01 · ROBINS CHAD M sold $2.4M2026-02-02 · ROBINS CHAD M sold $2.3M2026-01-05 · ROBINS CHAD M sold $1.9M2026-03-11 · ROBINS HARLAN S sold $1.9M2026-03-11 · ROBINS CHAD M sold $1.9M2025-12-15 · LO FRANCIS sold $1.8M2026-08-17 · NEUPERT PETER M sold $1.8M2026-06-15 · ROBINS HARLAN S sold $1.7M2026-03-11 · RUBINSTEIN JULIE sold $1.6M2026-01-12 · LO FRANCIS sold $1.4M2025-11-10 · ROBINS CHAD M sold $1.3M2026-04-06 · ROBINS CHAD M sold $1.2M2026-06-25 · GRIFFIN MICHELLE RENEE sold $1.1M2026-07-02 · LO FRANCIS sold $1.0M2026-08-17 · NEUPERT PETER M sold $1.0M2026-07-01 · LO FRANCIS sold $950.9K2026-03-11 · BENZENO SHARON sold $831.1K2026-03-03 · ROBINS CHAD M sold $785.4K2026-03-03 · GRIFFIN MICHELLE RENEE sold $735.1K2025-11-26 · ROBINS CHAD M sold $703.3K2026-06-04 · LO FRANCIS sold $695.1K2026-02-02 · ROBINS HARLAN S sold $644.8K2026-03-05 · LO FRANCIS sold $574.5K2026-04-08 · ROBINS CHAD M sold $566.0K2026-03-11 · BOBULSKY SUSAN sold $544.4K2026-03-04 · RUBINSTEIN JULIE sold $513.6K2025-12-03 · ROBINS HARLAN S sold $506.4K2026-08-26 · KATHERINE E OWEN filed to sell $250.0K2026-08-20 · Harlan Robins filed to sell $10.2M2026-08-19 · Harlan Robins filed to sell $5.5M2026-08-18 · ROBERT M HERSHBERG filed to sell $748.3K2026-08-18 · Harlan Robins filed to sell $6.4M2026-08-18 · Chad Robins filed to sell $6.8M2026-08-17 · PETER NEUPERT filed to sell $3.1M2026-08-17 · Chad Robins filed to sell $8.0M2026-08-17 · Harlan Robins filed to sell $7.5M2026-08-10 · SUSAN BOBULSKY filed to sell $74.8K2026-07-30 · SUSAN BOBULSKY filed to sell $29.3K2026-07-21 · Harlan Robins filed to sell $11.1M2026-07-16 · SUSAN BOBULSKY filed to sell $114.5K2026-07-02 · Harlan Robins filed to sell $8.2M2026-07-01 · SUSAN BOBULSKY filed to sell $10.4K2026-07-01 · FRANCIS LO filed to sell $4.3M2026-06-29 · SHARON BENZENO filed to sell $3.2M2026-06-26 · SHARON BENZENO filed to sell $260.6K2026-06-25 · MICHELLE GRIFFIN filed to sell $1.0M2026-06-25 · SUSAN BOBULSKY filed to sell $96.7K
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $78.9M sold by insiders over 180 days, 161 funds added last quarter, $76.9M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Adaptive Biotechnologies Corp insiders sold a net $78.9M of stock across 276 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
OWEN KATEY EINTERZ
Director
SELL
2026-08-26
9,615.0
$250.0K
ROBINS CHAD M
CEO and Chairman
SELL
2026-08-18
278,472.0
$6.8M
ROBINS CHAD M
CEO and Chairman
SELL
2026-08-18
204.0
$5.1K
HERSHBERG ROBERT
Director
SELL
2026-08-18
15,000.0
$365.9K
HERSHBERG ROBERT
Director
SELL
2026-08-18
15,664.0
$382.4K
276 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 271 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
VIKING GLOBAL INVESTORS LP
29,993,708.0 sh
$643.4M
BlackRock, Inc.
15,139,159.0 sh
$324.7M
VANGUARD CAPITAL MANAGEMENT LLC
6,403,587.0 sh
$137.4M
WELLINGTON MANAGEMENT GROUP LLP
5,911,366.0 sh
$126.8M
VANGUARD PORTFOLIO MANAGEMENT LLC
5,476,231.0 sh
$117.5M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
KATHERINE E OWEN
FILED 2026-08-26
$250.0K
Harlan Robins
FILED 2026-08-20
$10.2M
Harlan Robins
FILED 2026-08-19
$5.5M
ROBERT M HERSHBERG
FILED 2026-08-18
$748.3K
Harlan Robins
FILED 2026-08-18
$6.4M
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Franklin Genomic Advancements ETF
$669.6K POSITION · AS OF 2026-03-31
3.1%
ALGER SMALL CAP FOCUS FUND
$21.1M POSITION · AS OF 2026-04-30
2.7%
ARK Genomic Revolution ETF
$29.9M POSITION · AS OF 2026-04-30
2.4%
Lord Abbett Micro-Cap Growth Fund
$4.6M POSITION · AS OF 2026-04-30
2.2%
Counterpoint Quantitative Equity ETF
$4.3M POSITION · AS OF 2026-03-31
2.0%
Alger Small Cap Growth Portfolio
$2.4M POSITION · AS OF 2026-03-31
1.8%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 4 registered trials, 1 still enrolling or running — a status change here is dated weeks before the press release
4
Not applicable
1 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Executive pay vs shareholder return
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$9.1M
$39.6M
$5.0M
-73%
+25%
2024
$5.0M
$8.4M
$2.4M
-90%
-7%
2023
$8.9M
$2.7M
$4.3M
-92%
-6%
2022
$8.9M
-$1.1M
$4.3M
-87%
-10%
2021
$8.8M
-$6.2M
$5.9M
-53%
+0%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$277.0M$179.0M$170.3M$185.3M
OPERATING INCOME$-57.1M$-162.5M$-227.0M$-200.2M
NET INCOME$-59.5M$-159.6M$-225.3M$-200.4M
EPS (DILUTED)-0.39-1.08-1.56-1.40
OPERATING CASH FLOW$-46.0M$-95.2M$-156.3M$-183.9M
CASH$70.5M$47.9M$65.1M$90.0M
LONG-TERM DEBT$126.6M$132.4M$130.7M$125.4M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →